Amalgamated Financial’s Travere Therapeutics TVTX Stock Holding History

Amalgamated Financial’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$188K	Buy	+7,293	New	+$194K	﹤0.01%	1924

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Amalgamated Financial's TVTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Travere Therapeutics (TVTX) in Q1 2022: 7,293 shares worth $188K. The stake represents ﹤0.01% of the portfolio and ranks #1924 among its holdings.

169 funds tracked by Wall St. Rank hold TVTX as of Q1 2022.

Amalgamated Financial held 7,293 shares of Travere Therapeutics worth $188K as of Q1 2022.
Travere Therapeutics was a new Amalgamated Financial position in Q1 2022.
Travere Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1924 holding.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.